Full-Time

Associate Director

Digital Execution

BeOne

BeOne

1,001-5,000 employees

Global oncology therapeutics discovery, development, manufacturing

Compensation Overview

$155.8k - $205.8k/yr

Remote in USA

Hybrid

Remote within the US, with 10–15% travel required.

Bachelor's, Master's, MBA

Category
Growth & Marketing (1)
Required Skills
Microsoft Office
Veeva
Social Media
Business Analytics

Get referred to BeOne

See people who can refer or advise you

Requirements
  • A minimum of 5 years of digital marketing experience, including experience in the pharmaceutical industry.
  • Experience leading the creation of brand media and digital strategy and execution plans, including campaigns that adhere to FDA promotional guidelines.
  • Experience with marketing technology platforms including Veeva, media management and reporting tools, content tagging and taxonomy systems such as Claravine, and artificial intelligence-enabled content or omnichannel orchestration tools.
  • A strong understanding of digital marketing channels, tools, and best practices.
  • Strong analytical skills and the ability to interpret data to drive decision-making.
  • Strong project management and organizational skills.
  • The ability to work in a fast-paced environment.
  • A bachelor's degree in business, marketing, life sciences, or a related field.
  • Proficiency with personal computers and Microsoft Office.
Responsibilities
  • Develop and execute comprehensive digital and non-personal promotion strategy for BRUKINSA aligned with the overall brand strategy and hematology franchise priorities.
  • Lead content development and segmented execution of campaign messages and tactics through websites, display banners, social media, non-personal promotion emails, paid search, and custom digital activations.
  • Guide channel strategy, non-personal promotion target-list prioritization, and content tailoring across the customer journey.
  • Represent digital materials submitted to the internal promotional review committee and ensure final materials meet business objectives and regulatory, legal, and compliance requirements.
  • Lead end-to-end planning, development, and execution of digital and non-personal promotion campaigns across display, social media, email, paid search, electronic health record and point-of-care channels, custom digital programs, and websites.
  • Monitor and analyze campaign performance with the business analytics team and media partners, providing insights and recommendations for optimization.
  • Lead the annual operating plan process for brand digital and non-personal promotion media, translate brand plans into media strategy, review return-on-investment models and analysis, and approve tactical recommendations within the allocated budget.
  • Identify and leverage digital opportunities with Digital Strategy and Enablement, Global Technology Solutions, and Advanced Analytics teams to enhance brand presence and drive growth.
  • Partner with cross-functional teams to ensure coverage and dissemination of key data publications.
  • Communicate digital and non-personal promotion plans and results to key stakeholders and serve as digital lead in priority organization workstreams as needed.
  • Manage the digital marketing budget for the BRUKINSA brand, including contract review, invoice review and approval, budget reconciliation, and phasing management.
  • Ensure effective allocation of resources to maximize return on investment.
Desired Qualifications
  • An MBA or other advanced degree.
  • Excellent communication and collaboration skills.

BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dongcheng District, China

Founded

2010

Get referred to BeOne

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
  • August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
  • Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.

What critics are saying

  • BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
  • Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
  • AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.

What makes BeOne unique

  • BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
  • BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
  • Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

401(k) Retirement Plan

Wellness Program

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

3%

1 year growth

-9%

2 year growth

-3%
Yahoo Finance
Sep 4th, 2026
BeOne secures US pharma-tariff exemption after $1B+ manufacturing investment, but pricing concessions raise margin concerns

BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.

Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

Yahoo Finance
Aug 5th, 2026
BeOne Medicines Q2 revenue up 30% to $1.7B as BRUKINSA sales top $1.2B globally

BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.

Yahoo Finance
Jul 23rd, 2026
BeOne CEO sells $34.6M in stock while retaining 50M+ shares

John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.

PR Newswire
Jul 21st, 2026
Seegene USA receives FDA emergency authorisation for first multiplex PCR test to diagnose viral causes of ulcerative skin lesions

Seegene USA has received Emergency Use Authorization from the FDA for its Allplex HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR test that simultaneously detects herpes simplex virus types 1 and 2, varicella-zoster virus, and monkeypox virus. It is the first multiplex PCR test designed to support differential diagnosis of viral causes of ulcerative skin lesions in the US market. These pathogens often present with similar clinical symptoms that are difficult to distinguish visually. Research presented at the 2024 Clinical Virology Symposium found that a multiplex PCR assay identified HSV, VZV, or MPXV in 54 out of 966 samples that had previously tested negative using single-pathogen methods. The assay was developed using Seegene's proprietary multiplex PCR technologies and automated product development platform.